Developer docs
API playgroundTry for free, no card

Search company profiles

Marengo Therapeutics

Full company profile

uuid0000a6c

Namestring
Marengo Therapeutics
Legal namestring
Marengo Therapeutics, Inc.
Websiteurl
marengotx.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Marengo Therapeutics is a privately held, clinical-stage biotech founded in 2015 and headquartered in Cambridge, Massachusetts, that develops novel TCR-targeting antibodies to selectively modulate disease-specific T cell subsets for cancer and autoimmune indications. The company's scientific platform is built on three proprietary technology pillars — STAR (Bi-specific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters) — each grounded in first-in-class antibody libraries that target germline-encoded Variable β (Vβ) chain variants of the T cell receptor, a mechanism distinct from checkpoint inhibitors and conventional bispecifics. The lead clinical asset, Invikafusp alfa (STAR0602), is a dual T cell agonist designed to selectively activate Vβ6/10 T cells, a subset highly prevalent in tumor-infiltrating lymphocytes; the candidate is being evaluated both as monotherapy and in combination with Gilead's TRODELVY across the STARt-001 and STARt-002 Phase 1/2 trials in PD-1-resistant solid tumors, with interim Phase 2 data showing 20% overall response rate and 80% disease control rate across seven tumor types and confirmed complete responses in metastatic breast cancer combinations.

Marengo operates pre-commercial, generating no product revenue, and distributes its investigational therapies exclusively through clinical trial enrollment at over 20 academic cancer centers across North America and Europe, including MD Anderson, Dana-Farber, Memorial Sloan Kettering, Gustave Roussy, and VHIO. The company's go-to-market economics are anchored on milestone-based strategic collaborations rather than direct commercialization: a 2024 partnership with Ipsen for co-development of STAR program assets is valued at up to $2.8 billion in upfront and milestone payments, and a 2024 collaboration with Gilead secures TRODELVY supply for the STARt-002 combination study. The company was incubated and is wholly backed by ATP (Apple Tree Partners), which provided the $80 million Series A in November 2021, and the FDA granted Fast Track designation to Invikafusp alfa in advanced colorectal cancer with TMB-H in January 2025. The company employs 11–50 people across research, clinical development, regulatory, and corporate functions, and markets itself primarily through scientific conferences (SITC, AACR, ESMO, SABCS) and peer-reviewed publications rather than traditional commercial channels.

Short descriptiontext

Marengo Therapeutics is a clinical-stage biotech developing first-in-class TCR-targeting antibodies (STAR, TriSTAR, MSTAR platforms) that selectively modulate Vβ T cell subsets for cancer and autoimmune diseases, with lead asset Invikafusp alfa in Phase 2 trials across PD-1-resistant solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer immunotherapy, TCR-targeting antibodies, bispecific antibodies, T cell agonists, oncology biologics
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Immunotherapy Biologics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pipeline development and potential commercialization
TypeLicensing Royalties
Description

As a clinical-stage biotech, Marengo is pre-revenue. The company is developing novel TCR-targeting antibody therapies for cancer treatment. Revenue potential exists through future product commercialization and strategic partnerships including co-development agreements and milestone payments.

fiercebiotech.com
2Strategic partnerships and collaborations
TypeLicensing Royalties
Description

Marengo has established strategic partnerships with Ipsen (valued at $2.8B) and Gilead Sciences for co-development of combination therapies. These partnerships generate upfront payments, milestone payments, and potential royalties on future sales.

marengotx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1STAR Platform
Description

Bi-specific Selective Dual T Cell Agonists platform — first-in-class antibody library enabling selective modulation of Vβ TCR variants to activate specific T cell subsets for cancer treatment.

marengotx.com
+2 more records
Core offering1 text field

Marengo Therapeutics is a clinical-stage biotech developing TCR-targeting antibody therapies through three proprietary platforms (STAR, TriSTAR, MSTAR) that selectively modulate disease-specific T cell subsets to combat cancer and autoimmune disease. The lead candidate, Invikafusp alfa (STAR0602), is in Phase 2 clinical trials for advanced solid tumors, including combination studies with TRODELVY for metastatic breast cancer. Multiple additional candidates (STAR0603, STAR0501, STAR0502, TriSTAR0701, TriSTAR0705, MSTAR0801) are advancing through preclinical and Phase 1 development, with select assets partnered with Ipsen.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 20% overall response rate and 80% disease control rate in Phase 2 trial of Invikafusp alfa across seven major solid tumor types in PD-1-resistant cancers
+3 more records
Product overview1 text field

Marengo Therapeutics is a clinical-stage biotech company pioneering a novel approach to cancer immunotherapy through three proprietary technology platforms: STAR (Bispecific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters). The lead product is invikafusp alfa (STAR0602), the first dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells. The company is developing multiple candidates across these platforms including STAR0603, STAR0501 (partnered with Ipsen), STAR0502, TriSTAR0701 targeting Nectin-4, TriSTAR0705, and MSTAR0801 for autoimmune diseases. Invikafusp alfa is being studied as monotherapy and in combination with Gilead's TRODELVY in the STARt-002 trial for metastatic breast cancer.

Product and service8 records
1Invikafusp alfa (STAR0602)
CategoryOncology Biologic — T cell agonist (investigational)
Description

First-in-class dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells by combining non-clonal TCR activation with a T cell co-stimulatory signal in a single molecule. Being studied as monotherapy in STARt-001 across advanced solid tumors (including PD-1-resistant cancers and TMB-H colorectal cancer) and in combination with TRODELVY (sacituzumab govitecan) in the STARt-002 trial for metastatic breast cancer. FDA Fast Track designation granted in TMB-H colorectal cancer.

2STAR0603
CategoryOncology Biologic — Bispecific T cell agonist (investigational)
Description

Bispecific candidate from Marengo's precision T cell agonist STAR platform in development.

3STAR0501
CategoryOncology Biologic — T cell agonist (investigational, partnered)
Description

STAR program candidate partnered with Ipsen under the $2.8B strategic partnership, advancing in Phase 1 clinical development.

4STAR0502
CategoryOncology Biologic — T cell agonist (investigational, partnered)
Description

STAR program candidate partnered with Ipsen under the $2.8B strategic partnership.

5TriSTAR0701 (Nectin-4)
CategoryOncology Biologic — Trispecific T cell engager (investigational)
Description

Trispecific TriSTAR candidate targeting Nectin-4 for bladder and other solid tumor indications.

6TriSTAR0705
CategoryOncology/Autoimmune Biologic — Trispecific T cell engager (investigational)
Description

Trispecific TriSTAR candidate in development for oncology and autoimmune indications.

7MSTAR0801
CategoryAutoimmune Biologic — Precision T cell depleter (investigational)
Description

MSTAR platform candidate using precision T cell depletion to address T cell-mediated autoimmune diseases.

8IPN60300
CategoryOncology Biologic — Antibody-Drug Conjugate (investigational)
Description

Antibody-drug conjugate (ADC) in Phase I/II trials, distinct from Marengo's core STAR platform programs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Marengo established a strategic partnership with Ipsen valued at up to $2.8 billion for the co-development of STAR program assets including IPN01203/STAR0501. Ipsen is advancing the STAR0501 program in Phase 1, selected for presentation at AACR 2026's New Drugs on the Horizon session.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaboration with Gilead for supply of TRODELVY (sacituzumab govitecan) in the STARt-002 clinical trial investigating Invikafusp alfa in combination with TRODELVY for metastatic breast cancer. Marengo is the sponsor of the clinical study.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Werewolf Therapeutics develops tumor-activated immune modulators (PREDATOR platform) for cancer. Comparable to Marengo as a clinical-stage biotech developing novel immuno-oncology antibody-based therapeutics.

TypeDirect peer
Description

Immunocore is a clinical-stage biotech developing TCR-based immunotherapies for cancer and infectious diseases, with FDA-approved tebentafusp. Most directly comparable to Marengo as both companies leverage TCR biology to redirect T cell responses against tumors, though Immunocore uses soluble TCRs while Marengo targets Vβ chain variants with antibodies.

TypeDirect peer
Description

Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the FDA-approved Tecelra for synovial sarcoma. Highly comparable to Marengo given both companies leverage TCR biology to target cancer, though Adaptimmune's modality is cell therapy (TCR-T) versus Marengo's antibody-based approach.

TypeDirect peer
Description

Harpoon Therapeutics developed T cell engagers (TriTACs and ProTriTACs) targeting solid tumors and was acquired by Merck. Directly comparable to Marengo's TriSTAR tri-specific T cell engager platform given both companies focus on engaging T cells to attack solid tumors with engineered antibody constructs.

TypeDirect peer
Description

Janux Therapeutics develops T cell engagers (TRACTrs) for solid tumors using a tumor-activated masking technology. Directly comparable as a clinical-stage biotech focused on T cell engager therapeutics for cancer, with similar pipeline stage and target indications.

6Dragonfly Therapeutics
TypeDirect peer
Description

Dragonfly Therapeutics develops NK cell engagers and immune modulators using its TriNKET platform for oncology and autoimmune indications. Comparable to Marengo given its focus on engaging immune cells (NK cells via TriNKETs) for tumor killing, similar in approach to Marengo's T cell-focused platforms.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage biotech developing diversified oncology therapeutics including T cell engagers and immune modulators. Comparable to Marengo as a clinical-stage oncology company with multiple programs and similar business model of licensing/partnering pipeline assets.

TypeEmerging player
Description

Bolt Biotherapeutics develops ISAC (Immune-Stimulating Antibody Conjugates) that combine tumor-targeting antibodies with immune stimulants. Comparable to Marengo as a clinical-stage cancer immunotherapy company developing next-generation antibody-based therapeutics.

TypeEmerging player
Description

Compugen is a clinical-stage biotech leveraging AI/computational biology to discover novel immune checkpoints and develop antibody-based cancer immunotherapies. Comparable to Marengo in its focus on T cell-based immuno-oncology approaches with antibody therapeutics, though Compugen's targets are computational predictions.

TypeBroad incumbent
Description

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including bispecific DART molecules and antibody-drug conjugates. Comparable to Marengo as an established clinical-stage antibody therapeutics developer, with broader pipeline across multiple solid tumor types.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marengo Therapeutics

Cancer Immunotherapy Biologicsmarengotx.com

Marengo Therapeutics is a clinical-stage biotech developing first-in-class TCR-targeting antibodies (STAR, TriSTAR, MSTAR platforms) that selectively modulate Vβ T cell subsets for cancer and autoimmune diseases, with lead asset Invikafusp alfa in Phase 2 trials across PD-1-resistant solid tumors.

What Marengo Therapeutics does

Marengo Therapeutics is a privately held, clinical-stage biotech founded in 2015 and headquartered in Cambridge, Massachusetts, that develops novel TCR-targeting antibodies to selectively modulate disease-specific T cell subsets for cancer and autoimmune indications. The company's scientific platform is built on three proprietary technology pillars — STAR (Bi-specific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters) — each grounded in first-in-class antibody libraries that target germline-encoded Variable β (Vβ) chain variants of the T cell receptor, a mechanism distinct from checkpoint inhibitors and conventional bispecifics. The lead clinical asset, Invikafusp alfa (STAR0602), is a dual T cell agonist designed to selectively activate Vβ6/10 T cells, a subset highly prevalent in tumor-infiltrating lymphocytes; the candidate is being evaluated both as monotherapy and in combination with Gilead's TRODELVY across the STARt-001 and STARt-002 Phase 1/2 trials in PD-1-resistant solid tumors, with interim Phase 2 data showing 20% overall response rate and 80% disease control rate across seven tumor types and confirmed complete responses in metastatic breast cancer combinations.

Marengo operates pre-commercial, generating no product revenue, and distributes its investigational therapies exclusively through clinical trial enrollment at over 20 academic cancer centers across North America and Europe, including MD Anderson, Dana-Farber, Memorial Sloan Kettering, Gustave Roussy, and VHIO. The company's go-to-market economics are anchored on milestone-based strategic collaborations rather than direct commercialization: a 2024 partnership with Ipsen for co-development of STAR program assets is valued at up to $2.8 billion in upfront and milestone payments, and a 2024 collaboration with Gilead secures TRODELVY supply for the STARt-002 combination study. The company was incubated and is wholly backed by ATP (Apple Tree Partners), which provided the $80 million Series A in November 2021, and the FDA granted Fast Track designation to Invikafusp alfa in advanced colorectal cancer with TMB-H in January 2025. The company employs 11–50 people across research, clinical development, regulatory, and corporate functions, and markets itself primarily through scientific conferences (SITC, AACR, ESMO, SABCS) and peer-reviewed publications rather than traditional commercial channels.

Marengo Therapeutics firmographics

Firmographics
Name
Marengo Therapeutics
Legal name
Marengo Therapeutics, Inc.
Website
https://marengotx.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Marengo Therapeutics is a clinical-stage biotech developing first-in-class TCR-targeting antibodies (STAR, TriSTAR, MSTAR platforms) that selectively modulate Vβ T cell subsets for cancer and autoimmune diseases, with lead asset Invikafusp alfa in Phase 2 trials across PD-1-resistant solid tumors.
Ownership category
akta.pro rank

Marengo Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • Cancer immunotherapy
  • TCR-targeting antibodies
  • Bispecific antibodies
  • T cell agonists
  • Oncology biologics

Where Marengo Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Marengo Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Pipeline development and potential commercialization: As a clinical-stage biotech, Marengo is pre-revenue. The company is developing novel TCR-targeting antibody therapies for cancer treatment. Revenue potential exists through future product commercialization and strategic partnerships including co-development agreements and milestone payments.
  2. Strategic partnerships and collaborations: Marengo has established strategic partnerships with Ipsen (valued at $2.8B) and Gilead Sciences for co-development of combination therapies. These partnerships generate upfront payments, milestone payments, and potential royalties on future sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Marengo Therapeutics product offering

Product offering

Core offering

Marengo Therapeutics is a clinical-stage biotech developing TCR-targeting antibody therapies through three proprietary platforms (STAR, TriSTAR, MSTAR) that selectively modulate disease-specific T cell subsets to combat cancer and autoimmune disease. The lead candidate, Invikafusp alfa (STAR0602), is in Phase 2 clinical trials for advanced solid tumors, including combination studies with TRODELVY for metastatic breast cancer. Multiple additional candidates (STAR0603, STAR0501, STAR0502, TriSTAR0701, TriSTAR0705, MSTAR0801) are advancing through preclinical and Phase 1 development, with select assets partnered with Ipsen.

Product overview

Marengo Therapeutics is a clinical-stage biotech company pioneering a novel approach to cancer immunotherapy through three proprietary technology platforms: STAR (Bispecific Selective Dual T Cell Agonists), TriSTAR (Tri-specific Precision T Cell Engagers), and MSTAR (Novel Precision T Cell Depleters). The lead product is invikafusp alfa (STAR0602), the first dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells. The company is developing multiple candidates across these platforms including STAR0603, STAR0501 (partnered with Ipsen), STAR0502, TriSTAR0701 targeting Nectin-4, TriSTAR0705, and MSTAR0801 for autoimmune diseases. Invikafusp alfa is being studied as monotherapy and in combination with Gilead's TRODELVY in the STARt-002 trial for metastatic breast cancer.

Differentiator

Problem solved

Functional benefit

Brands

  • STAR Platform: Bi-specific Selective Dual T Cell Agonists platform — first-in-class antibody library enabling selective modulation of Vβ TCR variants to activate specific T cell subsets for cancer treatment.
  • TriSTAR Platform
  • MSTAR Platform

Products and services

  • Invikafusp alfa (STAR0602) First-in-class dual T cell agonist from the STAR platform that selectively activates Vβ6/10 T cells by combining non-clonal TCR activation with a T cell co-stimulatory signal in a single molecule. Being studied as monotherapy in STARt-001 across advanced solid tumors (including PD-1-resistant cancers and TMB-H colorectal cancer) and in combination with TRODELVY (sacituzumab govitecan) in the STARt-002 trial for metastatic breast cancer. FDA Fast Track designation granted in TMB-H colorectal cancer.
  • STAR0603 Bispecific candidate from Marengo's precision T cell agonist STAR platform in development.
  • STAR0501 STAR program candidate partnered with Ipsen under the $2.8B strategic partnership, advancing in Phase 1 clinical development.
  • STAR0502 STAR program candidate partnered with Ipsen under the $2.8B strategic partnership.
  • TriSTAR0701 (Nectin-4) Trispecific TriSTAR candidate targeting Nectin-4 for bladder and other solid tumor indications.
  • TriSTAR0705 Trispecific TriSTAR candidate in development for oncology and autoimmune indications.
  • MSTAR0801 MSTAR platform candidate using precision T cell depletion to address T cell-mediated autoimmune diseases.
  • IPN60300 Antibody-drug conjugate (ADC) in Phase I/II trials, distinct from Marengo's core STAR platform programs.

Quantifiable outcome

  • 20% overall response rate and 80% disease control rate in Phase 2 trial of Invikafusp alfa across seven major solid tumor types in PD-1-resistant cancers
  • +3 more outcomes

Companies that use Marengo Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Marengo Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Marengo Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and major.

  • IpsencoreStrategic or Co-development Partner · 1 January 2024Marengo established a strategic partnership with Ipsen valued at up to $2.8 billion for the co-development of STAR program assets including IPN01203/STAR0501. Ipsen is advancing the STAR0501 program in Phase 1, selected for presentation at AACR 2026's New Drugs on the Horizon session.
  • Gilead SciencesmajorStrategic or Co-development Partner · 1 January 2024Collaboration with Gilead for supply of TRODELVY (sacituzumab govitecan) in the STARt-002 clinical trial investigating Invikafusp alfa in combination with TRODELVY for metastatic breast cancer. Marengo is the sponsor of the clinical study.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Marengo Therapeutics competitors and assessment

Company assessment

Emerging players

  • Werewolf Therapeutics: Werewolf Therapeutics develops tumor-activated immune modulators (PREDATOR platform) for cancer. Comparable to Marengo as a clinical-stage biotech developing novel immuno-oncology antibody-based therapeutics.
  • Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing diversified oncology therapeutics including T cell engagers and immune modulators. Comparable to Marengo as a clinical-stage oncology company with multiple programs and similar business model of licensing/partnering pipeline assets.
  • Bolt Biotherapeutics: Bolt Biotherapeutics develops ISAC (Immune-Stimulating Antibody Conjugates) that combine tumor-targeting antibodies with immune stimulants. Comparable to Marengo as a clinical-stage cancer immunotherapy company developing next-generation antibody-based therapeutics.
  • Compugen: Compugen is a clinical-stage biotech leveraging AI/computational biology to discover novel immune checkpoints and develop antibody-based cancer immunotherapies. Comparable to Marengo in its focus on T cell-based immuno-oncology approaches with antibody therapeutics, though Compugen's targets are computational predictions.

Direct peers

  • Immunocore Holdings: Immunocore is a clinical-stage biotech developing TCR-based immunotherapies for cancer and infectious diseases, with FDA-approved tebentafusp. Most directly comparable to Marengo as both companies leverage TCR biology to redirect T cell responses against tumors, though Immunocore uses soluble TCRs while Marengo targets Vβ chain variants with antibodies.
  • Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, including the FDA-approved Tecelra for synovial sarcoma. Highly comparable to Marengo given both companies leverage TCR biology to target cancer, though Adaptimmune's modality is cell therapy (TCR-T) versus Marengo's antibody-based approach.
  • Harpoon Therapeutics: Harpoon Therapeutics developed T cell engagers (TriTACs and ProTriTACs) targeting solid tumors and was acquired by Merck. Directly comparable to Marengo's TriSTAR tri-specific T cell engager platform given both companies focus on engaging T cells to attack solid tumors with engineered antibody constructs.
  • Janux Therapeutics: Janux Therapeutics develops T cell engagers (TRACTrs) for solid tumors using a tumor-activated masking technology. Directly comparable as a clinical-stage biotech focused on T cell engager therapeutics for cancer, with similar pipeline stage and target indications.
  • Dragonfly Therapeutics: Dragonfly Therapeutics develops NK cell engagers and immune modulators using its TriNKET platform for oncology and autoimmune indications. Comparable to Marengo given its focus on engaging immune cells (NK cells via TriNKETs) for tumor killing, similar in approach to Marengo's T cell-focused platforms.

Broad incumbents

  • Macrogenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including bispecific DART molecules and antibody-drug conjugates. Comparable to Marengo as an established clinical-stage antibody therapeutics developer, with broader pipeline across multiple solid tumor types.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Marengo Therapeutics social profiles

Digital presence

Marengo Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marengo Therapeutics leadership team

Management profile

Number of profiles

Profiles21 records

Marengo Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marengo Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marengo Therapeutics

What does Marengo Therapeutics do?

Marengo Therapeutics is a clinical-stage biotech developing TCR-targeting antibody therapies through three proprietary platforms (STAR, TriSTAR, MSTAR) that selectively modulate disease-specific T cell subsets to combat cancer and autoimmune disease. The lead candidate, Invikafusp alfa (STAR0602), is in Phase 2 clinical trials for advanced solid tumors, including combination studies with TRODELVY for metastatic breast cancer. Multiple additional candidates (STAR0603, STAR0501, STAR0502, TriSTAR0701, TriSTAR0705, MSTAR0801) are advancing through preclinical and Phase 1 development, with select assets partnered with Ipsen.

Is Marengo Therapeutics a public or private company?

Marengo Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Marengo Therapeutics founded?

Marengo Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Marengo Therapeutics based?

Marengo Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Marengo Therapeutics make money?

Two revenue lines are on record. Pipeline development and potential commercialization is the primary driver. The others are strategic partnerships and collaborations.

Who are Marengo Therapeutics's main competitors?

Emerging players on record are Werewolf Therapeutics, Cullinan Oncology, Bolt Biotherapeutics and Compugen. Direct peers are Immunocore Holdings, Adaptimmune Therapeutics, Harpoon Therapeutics, Janux Therapeutics and Dragonfly Therapeutics. Macrogenics is listed as a broad incumbent.

Does Marengo Therapeutics have an API?

No public API is recorded for Marengo Therapeutics.

What industry is Marengo Therapeutics in?

Marengo Therapeutics's product category is Cancer Immunotherapy Biologics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2Marengo Therapeutics announced Phase 2 results for its bispecific antibody invikafusp alfa at ESMO 2026, showing tumor shrinkage in 56% of patients across eight tumor types. The 18% objective response rate and 60% disease control rate came from a first-in-human study, with better outcomes in patients previously treated with checkpoint inhibitors. The company plans late-stage development in 2027.PR NewswireMarengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress AfterThe FDA granted a second Fast Track Designation to invikafusp alfa for TMB-H solid tumors that progressed after prior treatment, expanding from colorectal cancer to a tissue-agnostic indication. The designation is supported by monotherapy responses across multiple tumor types in the STARt-001 study, with updated Phase 2 data to be presented at ESMO 2026.PR NewswireMarengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline ExpansionMarengo Therapeutics nominated its first development candidate under the TriSTAR collaboration with Ipsen, advancing the first program from the partnership. The company also appointed Saso Cemerski as Senior Vice President, Head of Immunology, to lead immunology research and expand its T-cell engager pipeline.AijournMarengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory BMarengo Therapeutics announced that key Phase 2 data from its STARt-001 study of invikafusp alfa has been selected for an oral presentation at the ESMO Congress 2026, evaluating the drug's single-agent activity in patients with PD-1-resistant solid tumors using biomarker-enriched cohorts including TMB-H. The company also appointed Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck who led the initial development of pembrolizumab (KEYTRUDA), to its Scientific Advisory Board to guide invikafusp alfa's next phase of development.PR NewswireMarengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory BMarengo Therapeutics announced that key Phase 2 data from the STARt-001 study of invikafusp alfa has been selected for an oral presentation at the ESMO Congress 2026, evaluating single-agent activity in patients with PD-1-resistant solid tumors using biomarker-enriched cohorts. The company also appointed Eric Rubin, former Senior Vice President of Global Clinical Oncology at Merck who led the initial development of pembrolizumab (KEYTRUDA), to its Scientific Advisory Board. The appointments aim to advance invikafusp alfa's development as both a single-agent therapy and potential combination backbone for heavily pretreated, biomarker-selected cancers.PR NewswireMarengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026Marengo Therapeutics announced late-breaking Phase 2a clinical results from the STARt-002 trial showing confirmed complete responses with invikafusp alfa plus TRODELVY® in heavily pretreated metastatic breast cancer patients across both TNBC and HR+/HER2- subtypes. The company also disclosed its second precision T cell activator from the STAR program, IPN01203/STAR0501, being advanced in partnership with Ipsen, selected for presentation at AACR 2026's New Drugs on the Horizon session. Enrollment in the STARt-002 trial is progressing rapidly at select cancer centers across North America with completion expected later this year.BioSpaceMarengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026Marengo Therapeutics announced late-breaking Phase 2a results from its STARt-002 trial of invikafusp alfa plus TRODELVY in metastatic breast cancer, showing confirmed complete responses in heavily pretreated patients. The company also unveiled its partner IPN01203/STAR0501 T cell activator in a Phase 1 trial with Ipsen. Enrollment is expected to complete later this year.OncoDailyZhen Su: Honoured to Join a Discussion on the Future of Oncology InnovationZhen Su, CEO of Marengo Therapeutics, participated in a discussion titled 'Beyond ‘Next-gen’: How Should We Engineer Future Breakthroughs?’ regarding the future of oncology innovation. The conversation focused on moving beyond incremental improvements to explore novel targets and new therapeutic paradigms in cancer treatment.OncoDailyZhen Su: Unlocking the Full Potential of Invika as a Next-Generation Immuno-Oncology BackboneZhen Su, CEO of Marengo Therapeutics, announced the company's participation in the 2026 J.P. Morgan Annual Healthcare Conference to present its immuno-oncology drug Invika. The company aims to complete two Phase 2a clinical trials in 2026 to evaluate Invika for patients with PD-1–resistant or refractory cancers.BioSpaceMarengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer SymposiumMarengo Therapeutics presented initial clinical results from its ongoing STARt-002 phase 1b/2 trial at the 2025 San Antonio Breast Cancer Symposium, evaluating the combination of Invikafusp alfa with TRODELVY® in patients with previously treated metastatic breast cancer. The combination demonstrated a safety profile consistent with known profiles of each agent, with selective expansion of Vβ6/10 T cells and early anti-tumor activity observed in the majority of patients, including two confirmed partial responses. A recommended phase 2 dose has been established and enrollment is ongoing in two phase 2 expansion cohorts for metastatic triple-negative breast cancer and HR+/HER2− metastatic breast cancer at select North American cancer centers.